PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28509812-7	2017	Ospemifene significantly improved fibrinogen and protein C antigen levels relative to placebo at months 3 (-8.7% vs -0.8% and -2.7% vs 0.5%, respectively), 6 (-6.0% vs 6.7% and -3.6 vs 8.0%), and 12 (-8.7% vs 7.3% and -4.5% vs 6.6%; P < 0.01, for all).	Ospemifene	0-10	fibrinogen beta chain	Homo sapiens	34-44
24055829-5	2013	Ospemifene binds ERalpha and ERbeta with approximately equal affinities.	Ospemifene	0-10	estrogen receptor 1	Homo sapiens	17-24
27922937-5	2017	RESULTS: The results showed that ospemifene induced expression of the key TH1 cytokines interferon gamma and interleukin-2 in vitro, which may be mediated by stimulating T-cells through phosphoinositide 3-kinase and calmodulin signaling pathways.	Ospemifene	33-43	negative elongation factor complex member C/D, Th1l	Mus musculus	74-77
27922937-5	2017	RESULTS: The results showed that ospemifene induced expression of the key TH1 cytokines interferon gamma and interleukin-2 in vitro, which may be mediated by stimulating T-cells through phosphoinositide 3-kinase and calmodulin signaling pathways.	Ospemifene	33-43	interferon gamma	Mus musculus	88-104
27922937-5	2017	RESULTS: The results showed that ospemifene induced expression of the key TH1 cytokines interferon gamma and interleukin-2 in vitro, which may be mediated by stimulating T-cells through phosphoinositide 3-kinase and calmodulin signaling pathways.	Ospemifene	33-43	interleukin 2	Mus musculus	109-122
25936229-3	2015	AREAS COVERED: This review describes the safety profile of SERMs (tamoxifen, raloxifene, toremifene, bazedoxifene, lasofoxifene, and ospemifene) and fulvestrant (a pure ER antagonist) from Phase III trials, long-term extension studies, and active comparator studies.	Ospemifene	133-143	estrogen receptor 1	Homo sapiens	9-11
26634778-2	2015	Ospemifene is a nonhormonal, estrogen receptor agonist/antagonist (ERAA) FDA-approved for the treatment of moderate to severe dyspareunia, a symptom of VVA, due to menopause.	Ospemifene	0-10	estrogen receptor 1	Homo sapiens	29-46
24918836-4	2014	Preclinical and clinical studies showed that ospemifene has an agonist action on bone and reduced the growth of all breast cancer models in animal studies, providing they expressed estrogen receptor-alpha.	Ospemifene	45-55	estrogen receptor 1	Homo sapiens	181-204
24055829-5	2013	Ospemifene binds ERalpha and ERbeta with approximately equal affinities.	Ospemifene	0-10	estrogen receptor 2	Homo sapiens	29-35
23665515-9	2013	Ospemifene showed similar affinity for estrogen receptor (ER)-alpha and ER-beta, but an overall lower affinity than estradiol.	Ospemifene	0-10	estrogen receptor 1	Rattus norvegicus	39-67
23665515-9	2013	Ospemifene showed similar affinity for estrogen receptor (ER)-alpha and ER-beta, but an overall lower affinity than estradiol.	Ospemifene	0-10	estrogen receptor 2	Rattus norvegicus	72-79
23985562-8	2013	These include vaginal lubricants and moisturizers, vaginal estrogen, hormone therapy, and the selective estrogen-receptor modulator ospemifene (indicated for dyspareunia).	Ospemifene	132-142	estrogen receptor 1	Homo sapiens	104-121
23852652-0	2013	Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.	Ospemifene	93-103	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-26
23852652-1	2013	PURPOSE: The objectives were to determine the cytochrome P450 (CYP) enzymes involved in the metabolism of ospemifene and its main hydroxylated metabolites and to examine the effects of CYP inhibitors and inducers on ospemifene pharmacokinetics.	Ospemifene	106-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	46-61
23852652-1	2013	PURPOSE: The objectives were to determine the cytochrome P450 (CYP) enzymes involved in the metabolism of ospemifene and its main hydroxylated metabolites and to examine the effects of CYP inhibitors and inducers on ospemifene pharmacokinetics.	Ospemifene	106-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
23852652-1	2013	PURPOSE: The objectives were to determine the cytochrome P450 (CYP) enzymes involved in the metabolism of ospemifene and its main hydroxylated metabolites and to examine the effects of CYP inhibitors and inducers on ospemifene pharmacokinetics.	Ospemifene	216-226	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-66
23852652-4	2013	RESULTS: Although several CYP inhibitors decreased the in vitro formation of ospemifene metabolites, none of them completely blocked metabolism.	Ospemifene	77-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
23852652-5	2013	Roles for CYP3A4, CYP2C9, CYP2C19 and CYP2B6 in the metabolism of ospemifene and its two main metabolites, 4--hydroxyospemifene and 4"-hydroxyospemifene, were confirmed.	Ospemifene	66-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	10-16
23852652-5	2013	Roles for CYP3A4, CYP2C9, CYP2C19 and CYP2B6 in the metabolism of ospemifene and its two main metabolites, 4--hydroxyospemifene and 4"-hydroxyospemifene, were confirmed.	Ospemifene	66-76	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	18-24
23852652-5	2013	Roles for CYP3A4, CYP2C9, CYP2C19 and CYP2B6 in the metabolism of ospemifene and its two main metabolites, 4--hydroxyospemifene and 4"-hydroxyospemifene, were confirmed.	Ospemifene	66-76	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	26-33
23852652-5	2013	Roles for CYP3A4, CYP2C9, CYP2C19 and CYP2B6 in the metabolism of ospemifene and its two main metabolites, 4--hydroxyospemifene and 4"-hydroxyospemifene, were confirmed.	Ospemifene	66-76	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	38-44
23852652-7	2013	CONCLUSIONS: The clinical pharmacokinetic findings and in vitro data suggest that CYP3A4 is important for ospemifene metabolism, but other CYP isoforms and metabolic pathways also contribute.	Ospemifene	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
23852652-7	2013	CONCLUSIONS: The clinical pharmacokinetic findings and in vitro data suggest that CYP3A4 is important for ospemifene metabolism, but other CYP isoforms and metabolic pathways also contribute.	Ospemifene	106-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	82-85
23852652-8	2013	Strong CYP3A or CYP2C9 inducers (e.g. rifampicin) would be expected to decrease the exposure to ospemifene.	Ospemifene	96-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	7-12
23852652-8	2013	Strong CYP3A or CYP2C9 inducers (e.g. rifampicin) would be expected to decrease the exposure to ospemifene.	Ospemifene	96-106	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	16-22
23852652-9	2013	Ospemifene should be used with caution when coadministered with the modest CYP3A inhibitor ketoconazole and should not be coadministered with the potent CYP3A/CYP2C9/CYP2C19 inhibitor fluconazole.	Ospemifene	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-80
18455292-6	2008	Osp also opposed apoptosis at least in U2OS/ERalpha cells.	Ospemifene	0-3	estrogen receptor 1	Homo sapiens	44-51
23880855-0	2013	Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo.	Ospemifene	11-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
23880855-1	2013	The objective of these investigations was to determine the possible effects of the novel selective estrogen receptor modulator, ospemifene, on cytochrome P450 (CYP)-mediated drug metabolism.	Ospemifene	128-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-158
23880855-1	2013	The objective of these investigations was to determine the possible effects of the novel selective estrogen receptor modulator, ospemifene, on cytochrome P450 (CYP)-mediated drug metabolism.	Ospemifene	128-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-163
23880855-2	2013	Ospemifene underwent testing for possible effects on CYP enzyme activity in human liver microsomes and in isolated human hepatocytes.	Ospemifene	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56
23880855-3	2013	Based on the results obtained in vitro, three Phase 1 crossover pharmacokinetic studies were conducted in healthy postmenopausal women to assess the in vivo effects of ospemifene on CYP-mediated drug metabolism.	Ospemifene	168-178	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	182-185
23880855-4	2013	Ospemifene and its main metabolites 4-hydroxyospemifene and 4"-hydroxyospemifene weakly inhibited a number of CYPs (CYP2B6, CYP2C9, CYP2C19, CYP2C8, and CYP2D6) in vitro.	Ospemifene	0-10	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	116-122
23880855-4	2013	Ospemifene and its main metabolites 4-hydroxyospemifene and 4"-hydroxyospemifene weakly inhibited a number of CYPs (CYP2B6, CYP2C9, CYP2C19, CYP2C8, and CYP2D6) in vitro.	Ospemifene	0-10	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	124-130
23880855-4	2013	Ospemifene and its main metabolites 4-hydroxyospemifene and 4"-hydroxyospemifene weakly inhibited a number of CYPs (CYP2B6, CYP2C9, CYP2C19, CYP2C8, and CYP2D6) in vitro.	Ospemifene	0-10	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	132-139
23880855-4	2013	Ospemifene and its main metabolites 4-hydroxyospemifene and 4"-hydroxyospemifene weakly inhibited a number of CYPs (CYP2B6, CYP2C9, CYP2C19, CYP2C8, and CYP2D6) in vitro.	Ospemifene	0-10	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	141-147
23880855-4	2013	Ospemifene and its main metabolites 4-hydroxyospemifene and 4"-hydroxyospemifene weakly inhibited a number of CYPs (CYP2B6, CYP2C9, CYP2C19, CYP2C8, and CYP2D6) in vitro.	Ospemifene	0-10	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	153-159
23880855-8	2013	Therefore, the risk that ospemifene will affect the pharmacokinetics of drugs that are substrates for CYP enzymes is low.	Ospemifene	25-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105
23729558-0	2013	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations.	Ospemifene	0-10	peptidylprolyl isomerase G	Homo sapiens	99-102
21564348-11	2012	Ospemifene and bazedoxifene exert anti-inflammatory effects in astrocytes by a mechanism involving classical oestrogen receptors and the inhibition of nuclear factor-kappa B p65 transactivation.	Ospemifene	0-10	synaptotagmin 1	Rattus norvegicus	174-177
21926925-11	2012	Ospemifene increased survival time and exerted an antitumor effect on the development and growth of estrogen receptor-positive mammary tumors in the MTag.Tg mouse model at the 50-mg/kg dose.	Ospemifene	0-10	estrogen receptor 1 (alpha)	Mus musculus	100-117
21926925-14	2012	CONCLUSIONS: Ospemifene prevents and treats estrogen receptor-positive MTag.Tg mammary tumors in this immune-intact mouse model in a dose-dependent fashion.	Ospemifene	13-23	estrogen receptor 1 (alpha)	Mus musculus	44-61
19533603-9	2010	Finally, we report that news SERMs, ospemifene and bazedoxifene, exert anti-inflammatory actions by a mechanism involving classical estrogen receptors and by the inhibition of LPS-induced NFkappaB p65 transactivation.	Ospemifene	36-46	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	197-200
18455292-11	2008	Osp opposed the effect of etoposide on OPG primarily in U2OS/ERbeta cells but interestingly, it had little effect on IL-6 expression.	Ospemifene	0-3	basic transcription factor 3 pseudogene 11	Homo sapiens	39-42
18455292-11	2008	Osp opposed the effect of etoposide on OPG primarily in U2OS/ERbeta cells but interestingly, it had little effect on IL-6 expression.	Ospemifene	0-3	estrogen receptor 2	Homo sapiens	61-67
18455292-12	2008	E2, PPT, DNP and Osp also inhibited etoposide-induced death and cytokine changes in SAOS-2 osteosarcoma cells expressing endogenous ERalpha and ERbeta.	Ospemifene	17-20	estrogen receptor 1	Homo sapiens	132-139
18455292-12	2008	E2, PPT, DNP and Osp also inhibited etoposide-induced death and cytokine changes in SAOS-2 osteosarcoma cells expressing endogenous ERalpha and ERbeta.	Ospemifene	17-20	estrogen receptor 2	Homo sapiens	144-150
15084346-4	2004	The maximum level of VEGF mRNA was observed at 1 h after raloxifene and 6 h after tamoxifen or ospemifene treatment.	Ospemifene	95-105	vascular endothelial growth factor A	Rattus norvegicus	21-25
17420779-12	2007	The effects of ospemifene and raloxifene were mediated by oestrogen receptors by a mechanism involving paracrine induction of osteoprotegerin in cultures with osteoblast derived osteosarcoma cells.	Ospemifene	15-25	TNF receptor superfamily member 11b	Homo sapiens	126-141
15255284-10	2004	Bone ALP decreased in 60 and 90 mg ospemifene groups by 1.9 and 2.6%, respectively (p < 0.05 for both dose levels when compared to placebo).	Ospemifene	35-45	alkaline phosphatase, placental	Homo sapiens	5-8
16280035-13	2005	In contrast, the ospemifene treatment significantly increased ER levels while tamoxifen significantly decreased them.	Ospemifene	17-27	estrogen receptor 1 (alpha)	Mus musculus	62-64
31953613-0	2020	Long non-coding RNA MALAT1 facilitates the tumorigenesis, invasion and glycolysis of multiple myeloma via miR-1271-5p/SOX13 axis.	Ospemifene	110-117	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	20-26
14501606-6	2003	Of the markers reflecting coagulation and fibrinolysis, plasma fibrinogen was significantly reduced in the 60- and 90-mg groups of ospemifene (8.7% and 8.5%, respectively) when compared with the placebo group.	Ospemifene	131-141	fibrinogen beta chain	Homo sapiens	63-73
34463164-10	2022	CONCLUSIONS: Up to date, this is the only prospective and observational study with ospemifene in routine clinical practice conditions and confirms the results previously reported from randomized controlled clinical trials, improving VVA, not increasing endometrial thickness, and decreasing CTx levels by exerting an anti-resorptive function.	Ospemifene	83-93	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	291-294
34464022-5	2021	US Food and Drug Administration (FDA)-approved treatment options include vaginally administered estrogen products as well as dehydroepiandrosterone (prasterone) and the selective estrogen receptor modulator ospemifene.	Ospemifene	207-217	estrogen receptor 1	Homo sapiens	179-196
34169794-8	2021	Oral ospemifene is an effective selective estrogen receptor modulator to treat VVA.	Ospemifene	5-15	estrogen receptor 1	Homo sapiens	42-59
32631589-1	2020	OBJECTIVES: To report the effects on the urinary function of ospemifene prescribed for vulvovaginal atrophy (VVA) in patients with overactive bladder (OAB) symptoms refractory to the first line of pharmacologic treatment with antimuscarinic or beta3-agonists drugs.	Ospemifene	61-71	T cell immune regulator 1, ATPase H+ transporting V0 subunit a3	Homo sapiens	244-249
32631589-10	2020	CONCLUSIONS: Ospemifene might be a useful option for postmenopausal women with VVA and OAB symptoms, refractory to the first line of treatment with beta3-agonists or antimuscarinic drugs, before considering invasive options.	Ospemifene	13-23	T cell immune regulator 1, ATPase H+ transporting V0 subunit a3	Homo sapiens	148-153
31953613-0	2020	Long non-coding RNA MALAT1 facilitates the tumorigenesis, invasion and glycolysis of multiple myeloma via miR-1271-5p/SOX13 axis.	Ospemifene	110-117	SRY-box transcription factor 13	Homo sapiens	118-123
31953613-11	2020	MALAT1 directly targeted miR-1271-5p and miR-1271-5p depression reverted the effects of MALAT1 knockdown on MM cells.	Ospemifene	29-36	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	0-6
31953613-11	2020	MALAT1 directly targeted miR-1271-5p and miR-1271-5p depression reverted the effects of MALAT1 knockdown on MM cells.	Ospemifene	45-52	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	0-6
31953613-11	2020	MALAT1 directly targeted miR-1271-5p and miR-1271-5p depression reverted the effects of MALAT1 knockdown on MM cells.	Ospemifene	45-52	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	88-94
31953613-12	2020	SOX13 was a target of miR-1271-5p and SOX13 overexpression weakened the effects of miR-1271-5p on MM.	Ospemifene	26-33	SRY-box transcription factor 13	Homo sapiens	0-5
31953613-12	2020	SOX13 was a target of miR-1271-5p and SOX13 overexpression weakened the effects of miR-1271-5p on MM.	Ospemifene	87-94	SRY-box transcription factor 13	Homo sapiens	0-5
31953613-12	2020	SOX13 was a target of miR-1271-5p and SOX13 overexpression weakened the effects of miR-1271-5p on MM.	Ospemifene	87-94	SRY-box transcription factor 13	Homo sapiens	38-43
31953613-13	2020	MALAT1 indirectly modulated SOX13 expression through targeting miR-1271-5p.	Ospemifene	67-74	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	0-6
31953613-13	2020	MALAT1 indirectly modulated SOX13 expression through targeting miR-1271-5p.	Ospemifene	67-74	SRY-box transcription factor 13	Homo sapiens	28-33
31953613-14	2020	MALAT1 down-regulation inhibited MM growth by miR-1271-5p/SOX13 axis in vivo.	Ospemifene	50-57	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	0-6
31953613-14	2020	MALAT1 down-regulation inhibited MM growth by miR-1271-5p/SOX13 axis in vivo.	Ospemifene	50-57	SRY-box transcription factor 13	Homo sapiens	58-63
31953613-15	2020	CONCLUSION: LncRNA MALAT1 expedited MM tumorigenesis, invasion, and glycolysis via miR-1271-5p/SOX13 axis.	Ospemifene	87-94	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	19-25
31953613-15	2020	CONCLUSION: LncRNA MALAT1 expedited MM tumorigenesis, invasion, and glycolysis via miR-1271-5p/SOX13 axis.	Ospemifene	87-94	SRY-box transcription factor 13	Homo sapiens	95-100
31915515-8	2019	RPS27A, UBC, and RAC1 were the top three proteins in our study; their corresponding RNAs were miR-1271-5p, miR-130a-3p, miR-130b-3p, and miR-574-3p.	Ospemifene	98-105	ribosomal protein S27a	Homo sapiens	0-6
31915515-8	2019	RPS27A, UBC, and RAC1 were the top three proteins in our study; their corresponding RNAs were miR-1271-5p, miR-130a-3p, miR-130b-3p, and miR-574-3p.	Ospemifene	98-105	Rac family small GTPase 1	Homo sapiens	17-21